SUPPLEMENTAL MATERIAL


Supplemental Tables

	Baseline before administration	7 days after administration	P value
Plasma prothrombin time (s)	11.1 ± 0.3	15.6 ± 4.5	0.347
Activated partial thromboplastin time (s)	25.0 ± 0.9	25.6 ± 1.2	0.535
Fibrinogen (g/L)	2.8 ± 0.2	3.3 ± 0.2	0.191
Alanine aminotransferase (U/L)	32.8 ± 2.1	33.4 ± 7.0	0.574
Aspartate aminotransferase (U/L)	29.7 ± 1.3	29.3 ± 7.2	0.429
Total bilirubin (μmol/L)	24.9 ± 3.5	24.6 ± 3.8	0.698
Blood glucose (mmol/L)	7.0 ± 0.7	6.4 ± 0.7	0.675
Blood urea nitrogen (mmol/L)	5.4 ± 0.4	4.1 ± 0.2	0.063
Serum creatinine (µmol/L)	88.1 ± 4.5	74.5 ± 3.5	0.067
K ⁺ (mmol/L)	4.0 ± 0.1	3.9 ± 0.1	0.236
Na ⁺ (mmol/L)	141.0 ± 0.5	140.5 ± 0.7	0.942
Cl ⁻ (mmol/L)	106.5 ± 0.8	104.4 ± 1.0	0.122
White blood cell counts (x10 ⁹ /L)	10.1 ± 1.3	6.9 ± 0.5	0.029
Red blood cell counts (x10 ⁹ /L)	4.4 ± 0.1	4.3 ± 0.2	0.618
Plate counts (x10 ⁹ /L)	216.2 ± 12.9	217.1 ± 15.3	0.962
Neutrophil counts (x10 ⁹ /L)	7.0 ± 1.2	5.0 ± 0.5	0.066
lymphocytes (x10 ⁹ /L)	2.4 ± 0.2	1.2 ± 0.1	0.012

Plus—minus values are means \pm SE. Comparisons were performed with paired sample t-test.

Supplementary Table 1. Laboratory data before and after fingolimod plus alteplase administration in patients with AIS

Supplemental Figures and Figure Legends



Supplementary Figure 1. Blood pressure and heart rate dynamic change during 24 hours after first dose of fingolimod plus alteplase. Blood pressure (BP) and heart rate (HR) were monitored during 24 hours after first dose. Upper curve stands for systolic blood pressure (SVP), and lower curve stands for diastolic blood pressure (DVP) on panel A. Heart rate temporal trajectories in groups after oral fingolimod on panel B. Values are mean ± SE; comparisons were performed with the ANOVA.